Benefits and Risks of TMS for Treatment-Resistant Major Depressive Disorder
TMS should be used in adults with major depressive disorder who have failed to respond to at least 2 adequate pharmacologic trials, as it provides meaningful symptom reduction and remission with minimal adverse effects. 1
Clinical Benefits
Efficacy in Treatment-Resistant Depression
The aggregate evidence demonstrates that rTMS significantly improves depressive symptoms and facilitates remission compared to sham treatment, with a number needed to treat of 3.4 to 9 patients for response and 5 to 7 patients for remission 1. Recent meta-analyses confirm response rates of approximately 29% in controlled trials, with remission rates reaching 42% in real-world settings 2, 3, 4.
- High-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation shows the most robust evidence base 1
- Theta burst stimulation (TBS) demonstrates comparable efficacy to conventional 10-Hz protocols but in significantly shorter treatment sessions 1
- Bilateral stimulation protocols show strong efficacy with SUCRA probabilities ranking among the top interventions 5
Important Caveat on Efficacy
One recent veteran-specific RCT found no significant differences between active rTMS and sham treatment in 164 patients with treatment-resistant depression and high rates of comorbid PTSD and substance use disorder 1. This raises the possibility that placebo effects from frequent clinical visits and patient expectancy may contribute substantially to outcomes. However, this single study was not sufficient to overturn the broader evidence base showing benefit 1.
Safety Profile and Adverse Effects
Minimal Serious Risks
TMS carries a low risk profile with no increased dropout rates due to adverse events (3.3% active vs 2.3% sham) or serious adverse events (0.9% active vs 1.5% sham) 6. The safety classification indicates:
- Low overall risk for standard rTMS protocols 7
- Medium risk for seizure induction, though this remains rare 7
- No evidence of tissue damage with proper protocols 7
Common Non-Serious Adverse Effects
The following side effects occur more frequently with active TMS but are typically mild and transient 6:
- Headaches: 22.6% (active) vs 16.2% (sham) - OR 1.48
- Pain at stimulation site: 23.8% (active) vs 5.2% (sham) - OR 8.09
- Discomfort: 10.9% (active) vs 5.0% (sham) - OR 1.98
- Scalp discomfort and noise during treatment 7
- Transient tingling, skin itching, or burning sensations 7
These effects resolve quickly after treatment and rarely lead to discontinuation 1, 6.
Treatment Parameters and Practical Considerations
Standard Protocol
- 20-30 treatment sessions delivered over 4-6 weeks 1
- Daily weekday sessions requiring frequent onsite visits
- Left prefrontal DLPFC targeting using standardized or neuronavigation-guided localization 1, 8
Accelerated and Alternative Protocols
- Theta burst stimulation reduces session time from 37.5 minutes to 3-10 minutes with similar efficacy 1
- Accelerated protocols (e.g., Stanford Neuromodulation Therapy) show promising preliminary results but require replication 3
- Insufficient evidence currently exists to recommend for or against intermittent TBS over standard rTMS 1
Critical Access Barrier
The primary challenge for rTMS implementation is access, as treatment requires frequent onsite visits over 4-6 weeks 1. This logistical burden limits real-world applicability despite demonstrated efficacy.
Comparison to Other Treatments
When compared to cognitive behavioral therapy (CBT) and antidepressants as first-line treatments, TMS is reserved for second-step therapy after medication failures 9, 10. However, TMS demonstrates superior tolerability compared to ECT, with fewer cognitive side effects and no requirement for anesthesia 2.
Predictive Factors and Personalization
No reliable method currently exists to predict which patients will respond before treatment begins 3. However, emerging evidence suggests:
- Patients with greater frontal lobe volume show better response rates 7
- Structural brain atrophy may interfere with treatment responsiveness 7
- Resting-state connectivity measures show promise as biomarkers but remain outside routine clinical use 3, 11
When to Use TMS
Initiate TMS after failure of 2 or more adequate antidepressant medication trials 1. Consider earlier in treatment algorithms for patients who:
- Cannot tolerate medication side effects
- Prefer non-pharmacologic interventions
- Have contraindications to antidepressants
Do not delay TMS indefinitely in treatment-resistant cases, as the benefits clearly outweigh the minimal and manageable adverse events 1.